Stock Options

12 Months Ended

Dec. 31, 2018

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Stock Options

14. Stock Options

The Company has four stock option plans, one adopted in September 1999 and amended in June 2000 (the “1999 Option Plan”, which expired in 2009), one adopted on November 8, 2000 (the “Directors’ Plan”), one adopted in July 2010 (the “2010 Option Plan”), and one adopted in April 2018. The 1999 Option Plan provided for the granting of up to 3,000,000 options; the Directors’ Plan provides for the granting of up to 400,000 options; the 2010 Option Plan provides for the granting of 4,000,000 options, and the 2018 Option Plan provides for the granting of 10,000,000 options.

On April 12, 2018 the Board of Directors approved the adoption of a 2018 Equity Compensation Plan. The Company has reserved 10,000,000 shares of our common stock for grants under this plan.

The 2018 Plan provides for the granting of both incentive and non-qualified stock options to key personnel, including officers, directors, consultants and advisors to the Company, at the discretion of the Board of Directors. Each plan limits the exercise price of the options at no less than the quoted market price of the common stock on the date of grant. The option term is determined by the Board of the Directors, provided that no option may be exercisable more than 10 years after the date of its grant and, in the case of an incentive option granted to an eligible employee owning more than 10% of the Company’s common stock, no more than five years after the date of the grant. Generally, under both plans, options to employees vest over three years at 33.33% per annum unless the Board of Directors designates a different vesting schedule.

On June 24, 2014, the Company filed a registration statement on Form S-8 with the Securities and Exchange Commission amending the shares of Common Stock included within its 2010 Stock Option from 2,000,000 shares to 4,000,000 shares.

The 2010 Plan provides for the granting of both incentive and non-qualified stock options to key personnel, including officers, directors, consultants and advisors to the Company, at the discretion of the Board of Directors. Each plan limits the exercise price of the options at no less than the quoted market price of the common stock on the date of grant. The option term is determined by the Board of the Directors, provided that no option may be exercisable more than 10 years after the date of its grant and, in the case of an Incentive Option granted to an eligible employee owning more than 10% of the Company’s common stock, no more than five years after the date of the grant. Generally, under both plans, options to employees vest over four years at 25% per annum, except for certain grants to employees that vest 25% upon grant with remaining amounts over two years at 50% and 25% per annum, respectively.

The Directors’ Plan provides for the granting of non-qualified options to members of the Board of Directors at exercise prices not less than the quoted market price of the common stock on the date of grant and options expire five years from the date of grant. In the event a person ceases to serve on the Board of Directors, the outstanding options expire one year from the date of cessation of service. Such options may be exercised commencing two years from the date of grant.

On April 12, 2018, the Company granted employees and directors options to purchase 4,475,000 shares of the Company’s common stock, at exercise prices ranging from $0.0189 to $0.208 per share.  The options vest over a three-year period and expire April 12, 2028.   The fair value of the options totaled $69,989 using the Black-Scholes option pricing model with the following assumptions: i) risk free interest rate of 2.64%, ii) expected life of 5 years, iii) dividend yield of 0%, iv) expected volatility of 217%. On April 30, 2018 our Executive Chairman and former CEO voluntarily cancelled the grant on April 12, 2018 of options awarded him to purchase an aggregate of 1,400,000 shares of the common stock.

On May 18, 2018, the Company, upon recommendation and approval by the compensation committee of the Board of Directors, granted its new Chief Executive Officer, options to purchase 6,500,000 shares of the Company’s common stock, at an exercise price of $0.017 per share. The options vest over a three-year period and expire May 18, 2028. The fair value of the options totaled $101,437 using the Black-Scholes option pricing model with the following assumptions: i) risk free interest rate of 2.64%; ii) expected life of 5 years; iii) dividend yield of 0%; iv) expected volatility of 217%.

On August 24, 2018, the Company granted one director options to purchase 5,000 shares of the Company’s common stock, at an exercise price of $0.045 per share. The options vest over a two year period and expire August 25, 2023. The quoted market price of the common stock at the time of issuance of the options was $0.045 per share. The fair value of the options totaled $223 using the Black-Scholes option pricing model with the following assumptions: i) risk free interest rate of 2.70%, ii) expected life of 5 years, iii) dividend yield of 0%, iv) expected volatility of 188%.

At December 31, 2018 there was $128,059 of unrecognized compensation cost related to nonvested share-based payments, which is expected to be recognized over a weighted-average period of 4 years. At December 31, 2017 there was $10,450 of unrecognized compensation cost related to nonvested share-based payments, which is expected to be recognized over a weighted-average period of 4 years.

The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the quoted price of the Company’s common stock for those awards that have an exercise price currently below the closing price. As of December 31, 2018 and 2017, the Company had options outstanding to purchase an aggregate of 11,785,000 and 3,180,000 shares respectively, with an exercise price above the quoted price of the Company’s stock, resulting in an  intrinsic value $285 and $0, respectively.

Additional information concerning the activity in the four option plans is as follows:

	2018						2017
	Options			Weighted Average Exercise Price			Options			Weighted Average Exercise Price
Outstanding, beginning of year		3,180,000		$	0.20.			3,365,500		$	0.20
Granted		10,980,000			0.02			5,000			0.03
Exercised		—			—			—			—
Forfeited		(1,408,334	)		(0.02	)		(36,667	)		(0.14	)
Expired		(966,666	)		(0.10	)		(153,833	)		(0.22	)
Outstanding, end of year		11,785,000			0.05			3,180,000		$	0.20
Exercisable, end of year		2,190,000			0.19			2,909,160		$	0.20
Options available for future grant, end of year		2,463,336						1,245,500

Additional information concerning the unvested options is as follows:

	2018						2017
	Options			Weighted Average Exercise Price			Options			Weighted Average Exercise Price
Non-Vested options at beginning of year		270,840		$	0.15			560,840		$	0.17
Granted		10,980,000			0.02			5,000			0.03
Vested		(247,506	)		(0.16	)		(258,333	)		(0.16	)
Forfeited		(1,408,334	)		(0.10	)		(36,667	)		(0.14	)
Cancelled		—			—			—			—
Non-Vested options end of year		9,595,000		$	0.02			270,840		$	0.15

Summarized information with respect to options outstanding under the four option plans at December 31, 2018 is as follows:

	Options Outstanding			Options Exercisable
Range of Exercise Price	Number Outstanding	Remaining Average Contractual Life (In Years)	Weighted Average Exercise Price	Number Exercisable	Weighted Average Exercise Price
$0.017 -$.0280	11,785,000	8.30	$0.050	2,190,000	$0.192

The estimated fair value of each stock option grant on the date of grant was computed using the following weighted-average assumptions:

	December 31,
	2018		2017
Risk-free interest rate	2.64% - 2.70	%	1.54	%
Expected term (life) of options (in years)	5		5
Expected dividends	—		—
Expected volatility	188% - 217	%	210	%